Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2025-05-30 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2025-05-30 English
Outcome of Board Meeting
Regulatory Filings
2025-05-26 English
Outcome of Board Meeting
Regulatory Filings
2025-05-26 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the re-constitution of the Nomination and Remuneration Committee of the Board of Directors. It specifies changes in the board committee members and their designations. The document is dated May 20, 2025, and is signed by the Company Secretary & Compliance Officer. There is no financial data, no mention of financial results, no audit information, no voting results, no legal proceedings, no capital changes, and no report publication. The content clearly relates to changes in the company's board committee structure, which falls under Board/Management Information filings. The document length is short (2053 characters), and it is a direct announcement of management changes, not a report or presentation. Therefore, the appropriate classification is MANG (Board/Management Information).
2025-05-20 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-19 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming Board Meeting scheduled to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2025. It references compliance with SEBI (LODR) Regulations, 2015, specifically Regulation 29, which pertains to Board Meeting disclosures. The document does not contain any financial data or results itself but is an announcement of the meeting where such results will be approved. The document length is short (2124 characters), and it serves as an intimation rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Annual Report (10-K) or Interim Report (IR).
2025-05-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.